Exscientia stock.

Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner.Nov 7, 2023 · Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently up 7.04% so far this month. During the month of November, Exscientia PLC (ADR)’s stock price has reached a high of $6.10 and a low of $5.15. Over the last year, Exscientia PLC (ADR) has hit prices as high as $11.52 and as low as $4.09. Year to date ... Like Recursion, Exscientia (NYSE: EXAI) uses AI in its approach to drug discovery.Unlike Recusion, Exscientia aims to develop bespoke drug solutions for patients. Exscientia was the first to bring ...Recent advancements in the Company’s pipeline, collaborations and operations as well as financial results for the fourth quarter and full year 2021 are summarised below. In addition, Exscientia will host a conference call on Thursday, March 24 at 12:30 p.m. GMT / 8:30 a.m. ET to provide an overview of the company's end-to-end …

Nov 24, 2023 · According to the issued ratings of 3 analysts in the last year, the consensus rating for Exscientia stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for EXAI. The average twelve-month price prediction for Exscientia is $10.25 with a high price target of $13.00 and a low price target of $7.00. Revenue: Revenue for the three and nine months ended September 30, 2023 was $10.8 million and $21.6 million respectively, compared to $7.7 million and $24.9 million for the three and nine months ...

Exscientia Plc has an analyst consensus of Moderate Buy, with a price target consensus of $14.00. See the top stocks recommended by analysts >> EXAI market cap is currently $883.3M and has a P/E ...

Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Jul 12, 2023 · Shares of Exscientia (EXAI 2.18%) ... The stock is up more than 38% so far this year. So what. Exscienta is an AI-driven precision medicine company that focuses on oncology therapies. The clinical ... Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, before the open of U.S. markets. The Company will host a ...Recent advancements in the Company’s pipeline, collaborations and operations as well as financial results for the fourth quarter and full year 2021 are summarised below. In addition, Exscientia will host a conference call on Thursday, March 24 at 12:30 p.m. GMT / 8:30 a.m. ET to provide an overview of the company's end-to-end technology ...

Exscientia Plc American Depositary Shares (EXAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Find real-time EXAI - Exscientia PLC stock quotes, company profile, news and forecasts from CNN Business.

Exscientia Stock Forecast 11-28-2023. Forecast target price for 11-28-2023: $ 6.01. Negative dynamics for Exscientia shares will prevail with possible volatility of 5.710%. Pessimistic target level: 5.81.View the latest Exscientia PLC ADR (EXAI) stock price, news, historical charts, analyst ratings and financial information from WSJ.Jun 15, 2021 · Exscientia, based in Oxford, England, is paying 50 million euros ($60.6 million) in a combination of cash and shares for the Vienna-based Allcyte, according to a company press release. Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023. 07/18/2023.Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...Shares of Exscientia ... The artificial intelligence (AI)-driven precision medicine biotech stock is up more than 47% so far this year. It closed last week at $6.04 a share, then rose to as high ...

If a therapeutic is commercialized, Exscientia will receive tiered royalties on product sales. The stock has lost 5.1% year to date through Tuesday, while the S&P 500 has gained 15.7%. -Tomi KilgoreThis reflects a positive earnings surprise of 26.19%. Look out for EXAI's next earnings release expected on March 28, 2024. For the next earning release, we expect the company to report earnings ...Like Recursion, Exscientia (NYSE: EXAI) uses AI in its approach to drug discovery.Unlike Recusion, Exscientia aims to develop bespoke drug solutions for patients. Exscientia was the first to bring ...Dec 1, 2023 · 2012. 481. Andrew Hopkins. https://www.exscientia.ai. Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and ... Exscientia Plc American Depositary Shares (EXAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

During the last session, Exscientia Plc ADR (NASDAQ:EXAI)’s traded shares were 0.42 million, with the beta value of the company hitting 0.73. At the end of the trading day, the stock’s price was $6.17, reflecting an intraday gain of 1.15% or $0.07. The 52-week high for the EXAI share is $11.52, that puts it down -86.71 from that peak though ...In October 2021, Exscientia was floated on the Nasdaq stock market, raising $510 million, the largest initial public offering for a European biotech ever. From small beginnings, with just five staff, Exscientia now employs over 400 people. Headquartered in England at the Oxford Science Park, Exscientia has a diverse global team with offices …

Find out all the key statistics for Exscientia plc (EXAI), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. ... Stock Price History. Beta ...It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that it has enrolled the first patient in its Phase 1/2 “ELUCIDATE” (GTAEXS617-001) study evaluating GTAEXS617 (‘617), Exscientia’s precision-designed CDK7 inhibitor, for the treatment of advanced solid tumours. The clinical trial will evaluate …The Exscientia plc stock price gained 2.18% on the last trading day (Friday, 17th Nov 2023), rising from $5.97 to $6.10. During the last trading day the stock fluctuated 7.85% from a day low at $5.86 to a day high of $6.32. The price has been going up and down for this period, and there has been a 4.99% gain for the last 2 weeks.May 27, 2021 · Within 3 weeks, Exscientia, a 2012 spinoff of the University of Dundee, UK, announced a $225 million Series D financing round (Table 1), along with a $300 million equity commitment that it can ... Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...

Exscientia PLC Sponsored ADR EXAI shares soared 13.5% in the last trading session to close at $5.29. The move was backed by solid volume with far more shares changing hands than in a normal session.

Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently up 2.78% so far this month. During the month of November, Exscientia PLC (ADR)’s stock price has reached a high of $6.10 and a low of $5.15. Over the last year, Exscientia PLC (ADR) has hit prices as high as $11.52 and as low as $4.09. Year to date ...

Legal Name Exscientia Ltd. Stock Symbol NASDAQ:EXAI. Company Type For Profit. Contact Email [email protected]. Phone Number +44-1865-818941. Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design ...May 24, 2023 · That made the stock quite an outlier, as the S&P 500 index slipped by 0.7% on the day. So what Exscientia, which harnesses AI in the discovery and development of pharmaceuticals, published its ... OXFORD, England-- (BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) announced today that it is expanding its technology management structure to accelerate application of Exscientia's innovative technologies to catalyse instrumental change in the way drug candidates are being discovered, designed and developed for patients in need …Real time Exscientia Plc (EXAI) stock price quote, stock graph, news & analysis.Exscientia (NASDAQ: EXAI) has to be one of the most exciting pharma stocks in relation to AI. It’s a relatively cheap stock with the potential to triple based on analysts’ consensus.That was the dynamic behind artificial intelligence (AI)-powered healthcare-solutions provider Exscientia 's ( EXAI 1.15%) more than 6% leap in share price on Wednesday. That made the stock quite ...OXFORD, U.K., November 09, 2023 -- ( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results ...Is Exscientia PLC (EXAI) a Stock to Watch After Gaining 4.96% This Week? InvestorsObserver - Oct 25, 2023, 10:22AM Phio Pharmaceuticals, Exscientia among …

View Exscientia PLC Sponsored ADR EXAI investment & stock information. Get the latest Exscientia PLC Sponsored ADR EXAI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Nov 29, 2023 · What is Exscientia's stock price target for 2024? 3 brokers have issued twelve-month price targets for Exscientia's shares. Their EXAI share price targets range from $7.00 to $13.00. On average, they predict the company's share price to reach $10.25 in the next year. This suggests a possible upside of 75.5% from the stock's current price. Feb 6, 2023 · Bristol Myers Squibb will oversee the clinical and commercial development and Exscientia, who designed the PKC theta inhibitor, is eligible for milestone payments and, if approved, tiered royalties on net product sales. In May 2021, Bristol Myers Squibb and Exscientia expanded the collaboration in immunology & inflammation indications and oncology. Instagram:https://instagram. vernova gecta etfbest llc nameshydrogen fuel cell stock Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you. public ai companiesretired military dental plan Date Filing Type Filing Description Download / View. November 9, 2023. 6-K. Report of Foreign Issuer. September 20, 2023. 6-K. Report of Foreign Issuer. August 10, 2023. 6-K. paypal dollar5 EXS73565. MALT1. * Phase 3 may not be required if Phase 2 is registrational: PKC-theta is in a Phase 1 healthy volunteer study. Does not include Sumitomo Pharma programmes. Our pipeline demonstrates our ability to rapidly translate scientific concepts and patient-centric data into precision-designed therapeutic candidates.Exscientia will receive an upfront payment of $20 million in cash and be eligible for milestone payments of up to $674 million in total. If a drug is commercialized, the company will also receive ...Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.